Grufity logo
Grufity logo
MNPR

MNPR - Monopar Therapeutics Inc Stock Price, Fair Value and News

$62.57+1.10 (+1.79%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

MNPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MNPR Price Action

Last 7 days

1.8%

Last 30 days

4.1%

Last 90 days

2.4%

Trailing 12 Months

84.1%

MNPR RSI Chart

MNPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MNPR Valuation

Market Cap

411.8M

Price/Earnings (Trailing)

-27.48

EV/EBITDA

-26.19

Price/Free Cashflow

-41.13

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

MNPR Fundamentals

MNPR Revenue

MNPR Earnings

Earnings (TTM)

-15.0M

Earnings Growth (Yr)

-48.31%

Earnings Growth (Qtr)

25.15%

MNPR Profitability

Return on Equity

-11.07%

Return on Assets

-10.86%

Free Cashflow Yield

-2.43%

MNPR Investor Care

Shares Dilution (1Y)

9.55%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2023----
2021----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Monopar Therapeutics Inc

MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
 CEO
 WEBSITEmonopartx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES11

Monopar Therapeutics Inc Frequently Asked Questions

MNPR is the stock ticker symbol of Monopar Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Monopar Therapeutics Inc is 411.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.